Shares of DBV Technologies S.A. (NASDAQ:DBVT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $45.25.
DBVT has been the topic of a number of research reports. Guggenheim lowered their target price on DBV Technologies from $51.00 to $46.00 and set a “buy” rating on the stock in a research report on Friday, October 30th. Citigroup restated a “market outperform” rating on shares of DBV Technologies in a research note on Thursday, October 29th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a report on Friday, October 30th. Citizens Jmp dropped their price objective on shares of DBV Technologies from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research note on Thursday, October 29th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of DBV Technologies in a report on Thursday, October 15th.
Check Out Our Latest Analysis on DBV Technologies
Institutional Trading of DBV Technologies
Several institutional investors and hedge funds have recently modified their holdings of DBVT. Vivo Capital LLC lifted its holdings in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock valued at $55,726,000 after purchasing an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in DBV Technologies during the first quarter worth $21,159,000. Perceptive Advisors LLC bought a new stake in DBV Technologies during the first quarter worth $20,146,000. Atika Capital Management LLC raised its position in DBV Technologies by 31.1% in the 1st quarter. Atika Capital Management LLC now owns 271,300 shares of the company’s stock valued at $5,667,000 after buying an additional 64,419 shares during the last quarter. Finally, Elmind Capital LP purchased a new stake in DBV Technologies in the 1st quarter valued at $5,536,000. 71.74% of the stock is owned by hedge funds and other institutional investors.
DBV Technologies Price Performance
Shares of DBVT opened at $10.45 on Monday. DBV Technologies has a one year low of $8.63 and a one year high of $26.18. The company has a market cap of $657.10 million, a PE ratio of -3.47 and a beta of -0.84. The stock has a 50-day moving average of $11.06 and a 200-day moving average of $16.70.
DBV Technologies (NASDAQ:DBVT – Get Free Report) last posted its quarterly earnings results on Wednesday, October 28th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.41). The firm had revenue of $1.60 million for the quarter, compared to analyst estimates of $0.56 million. DBV Technologies had a negative return on equity of 120.95% and a negative net margin of 5,392.17%. Analysts expect that DBV Technologies will post -2.22 EPS for the current fiscal year.
DBV Technologies Company Profile
DBV Technologies SA (NASDAQ: DBVT) is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.
DBV Technologies’ lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.
Featured Articles
- Five stocks we like better than DBV Technologies
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
